Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - REGENERX BIOPHARMACEUTICALS INCtm205314d1_ex32-1.htm
EX-31.1 - EXHIBIT 31.1 - REGENERX BIOPHARMACEUTICALS INCtm205314d1_ex31-1.htm
10-K - FORM 10-K - REGENERX BIOPHARMACEUTICALS INCtm205314d1_10k.htm

 

EXHIBIT 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statements on Form S-8 (Registration Nos. 333-168252, 333-152250 and 333-111386) of RegeneRx Biopharmaceuticals, Inc. (the “Company”) of our report, which includes an explanatory paragraph relating to the Company’s ability to continue as a going concern, dated March 20, 2020, on our audits of the financial statements of RegeneRx Biopharmaceuticals, Inc. as of December 31, 2019 and 2018 and for the years then ended, included in this Annual Report on Form 10-K for the year ended December 31, 2019.

 

/s/ CohnReznick LLP
 
Tysons, Virginia
March 20, 2020